Good MorningEquity markets continue to tread water as investors and traders wait on the next FOMC policy statement. The FOMC is not expected to hike rates next week, but it will remain hawkish and may surprise the market with its rhetoric. The takeaway is that interest rates will most likely remain high for an indefinite amount of time, which will have a bearing on stocks. With rates on treasuries above the S&P 500 dividend average, they pose a headwind to equity prices.
The market may remain in a holding pattern for the summer. If the S&P 500 can not get above the 4,300 level next week, it will be the top of a trading range that could dominate price action for several years. In that scenario, investors must be vigilant and use market dips to build positions in high-quality stocks. Featured: 5 dividend stocks worth owning in any market condition (Ad) 
|
Construction | |
Despite rising mortgage rates and a slightly cooling housing market, homebuilding stocks like Lennar (NYSE: LEN) and KB Homes (NYSE: KBH) are ripping higher and outperforming the S&P 500.
The sector was buoyed by positive earnings results from the likes of Redfin (NASDAQ: RDFN), Toll Brothers... Read the Full Story |
|
From Our Partners | | Renewed tensions involving Iran are putting global oil supplies back in focus - and history shows certain energy stocks respond before the broader market catches on.
A new report identifies three energy stocks emerging from today's supply disruptions. One is already benefiting from the current environment; the other two may not be on your radar yet. | | See which three energy stocks made the list and why they stand out |
|
Consumer Staples | |
If you’ve been looking for a good time to get into Ollie’s Bargain Outlook (NASDAQ: OLLI), that time could be now. The stock is pulling back after a solid report that brings nothing but good news for investors. The takeaways include shifting trends and accelerating purchasing habits, i... Read the Full Story |
|
Consumer Staples | |
Campbell Soup Company (NYSE: CPB) fell more than 6.5% following its Q3 report for no good reason. The company’s results were better than expected, and the guidance was reaffirmed and might be considered cautious. The news was no catalyst for the rally but also not a spark to send investors r... Read the Full Story |
|
From Our Partners | | Most AI portfolios hold the same handful of chip and software names - and completely ignore the physical layer. One perception-hardware company posted ~49% Q1 revenue growth with four partnership announcements in a single month.
A free report names seven companies building the automation, robotics, and semiconductor-test infrastructure that AI requires to move beyond the data center - including an automation giant that raised full-year guidance after quarterly sales rose ~12%. | | Click here to get your free copy of this report today |
|
Business Services | |
The story of Netflix Inc.'s (NASDAQ: NFLX) turnaround potential is getting investors' attention. The streamer's stock is up 23.71% in the past month, gapping up on May 18 following news that it has almost 5 million users of its advertising-supported service, and more than a quarter of new signups ... Read the Full Story |
|
Technology | |
Over the last five weeks, MicroVision (NASDAQ: MVIS) stock is up almost 300%, marching in an almost straight line upwards, with only two red days since the rally started.
The stock has become the subject of a short squeeze; social media hype and the company's past involvements in augmented realit... Read the Full Story |
|
From Our Partners | | Trader Graham Lindman has built a strategy around a repeating anomaly that appears in the first 60 minutes of every trading day - and it never requires holding positions overnight.
The setup has recently been refined to target up to 100% payouts by holding through the close, with 10 consecutive winning trades logged during one of the most volatile stretches since the Tariff Wars.
A new signal opportunity opens tomorrow. | | See how to join Graham Lindman's next trade before it opens |
|
Retail/Wholesale | |
If you are familiar with The Lovesac Company (NASDAQ: LOVE), you know many things to love about it. The furniture is attractive, comfortable, and high-quality, and its modular design is easy to use. You may also know that there are reasons to hate the stock. The brand came out of nowhere and took ... Read the Full Story |
|
Auto/Tires/Trucks | |
Lightning struck for Thor Industries (NYSE: THO) when lockdowns and social distancing became the norm, and it has struck again for this RV industry leader. The Q3 results are not excellent because sales are down high-double-digits compared to last year, but, regarding normalization within the indu... Read the Full Story |
|
Retail/Wholesale | |
Dave & Busters Entertainment (NASDAQ: PLAY) has had a rebound brewing for years. The company has worked diligently to overcome pandemic-inspired woes to become more prominent, stronger, and more profitable, yet the stock price lags its peers by a wide margin. One reason may be the analysts who... Read the Full Story |
|
Technology | |
Unity Software (NYSE: U) saw its share price rocket higher Monday afternoon and closed the day up almost 20% after Apple (NASDAQ: AAPL) announced they are working together on the Apple Vision Pro headset.
The breaking news caused Unity’s stock to break above the declining 200 SMA, tear abov... Read the Full Story |
|
Technology | |
In today's market, it would seem that every stock and company with the word 'technology' entrenched in its business model is enjoying a significant rally this month; the new sentiment comes from the breakthroughs seen during NVIDIA's (NASDAQ: NVDA) last quarterly performance.
Shares of NVIDIA ros... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland. | | View Today's Stock Pick |
|
